Charles Schwab Investment Management Inc. Boosts Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Charles Schwab Investment Management Inc. lifted its position in Vaxcyte, Inc. (NASDAQ:PCVX) by 47.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,295,837 shares of the company’s stock after purchasing an additional 419,600 shares during the quarter. Charles Schwab Investment Management Inc. owned about 1.04% of Vaxcyte worth $148,075,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Intech Investment Management LLC purchased a new position in Vaxcyte during the 3rd quarter worth approximately $3,226,000. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Vaxcyte by 59.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 70,037 shares of the company’s stock worth $8,003,000 after acquiring an additional 26,096 shares during the period. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of Vaxcyte during the third quarter worth $1,189,000. Meeder Asset Management Inc. lifted its position in Vaxcyte by 1,007.9% during the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock valued at $80,000 after purchasing an additional 635 shares during the period. Finally, Pathstone Holdings LLC boosted its holdings in Vaxcyte by 7.6% in the third quarter. Pathstone Holdings LLC now owns 30,527 shares of the company’s stock valued at $3,488,000 after purchasing an additional 2,154 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Price Performance

Shares of PCVX stock opened at $88.54 on Monday. Vaxcyte, Inc. has a 1-year low of $48.24 and a 1-year high of $121.06. The company has a market cap of $11.04 billion, a price-to-earnings ratio of -19.25 and a beta of 1.01. The stock has a 50 day simple moving average of $107.89 and a 200-day simple moving average of $89.57.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter last year, the firm earned ($0.91) EPS. Analysts anticipate that Vaxcyte, Inc. will post -4.14 earnings per share for the current fiscal year.

Insider Activity at Vaxcyte

In other news, COO Jim Wassil sold 10,000 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $111.93, for a total value of $1,119,300.00. Following the completion of the sale, the chief operating officer now directly owns 207,503 shares in the company, valued at $23,225,810.79. This represents a 4.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Elvia Cowan sold 5,000 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $107.67, for a total transaction of $538,350.00. Following the transaction, the senior vice president now owns 12,723 shares in the company, valued at $1,369,885.41. The trade was a 28.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 102,464 shares of company stock valued at $11,455,576. 3.10% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on PCVX shares. Mizuho lifted their price objective on Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research note on Tuesday, September 10th. Needham & Company LLC reissued a “buy” rating and issued a $140.00 price target on shares of Vaxcyte in a report on Wednesday, November 6th. Leerink Partners upped their price objective on Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 3rd. BTIG Research lifted their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Finally, Jefferies Financial Group boosted their target price on shares of Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $147.50.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.